Beso schreef op 24 november 2020 10:35:
goede samenvatting op Yahoo door Vader :
Just the Facts:
-160/165 patients enrolled. At current enrollment rate we’re looking at IV trial completion by end of this week
-175 compassionate use patients with 90 patients receiving Aviptadil and followed for 28 days demonstrating 72% survival vs 17% survival with SOC
-Confirmation by Relief that improvement in clinical status is directly correlated with earlier intervention
-No drug related adverse events have been reported…unlike vaccines which have risk of transverse myelitis, reinfection/superinfection
-25 community hospitals have been enrolled in the EAP program…this is very high for a compassionate use program indicating word of mouth is spreading (which I can confirm among intensivists)
-Patent is good for >5 years with potential indications for sarcoidosis, interstitial lung disease, COPD, immunotherapy induced pneumonitis
-IV, Inhaler trials ongoing with Q1 2021 results planned for early/moderate COVID and RDS
And lastly, a speculation:
-An “extraordinary” meeting is planned 12/17/20. It seems unlikely that Relief would plan salary increases and dilution unless they had big news to off set the bad. Possible merger, acquisition, OWS/BARDA or EUA are likely good news scenarios